拜耳（BAYN）股价上涨2.50%。公司宣布，已获得中国监管部门批准，可在中国上市一款用于预防复发性卒中的新药，从而拿下全球首个针对新一类药物的批准。
Bayer BAYN 2.50%increase; up pointing triangle said it received regulatory authorization to launch a new drug to prevent recurrent stroke in China, winning the first global approval for a new class of medicines.
这家德国制药集团表示，中国国家药品监督管理局的这一决定，使其获得了全球首个针对XIa因子抑制剂类药物的批准。这类药物旨在减缓一种调节人体凝血过程的蛋白质的活性，且不增加出血风险。
The German pharmaceutical group said the decision from China’s National Medical Products Administration hands it the first approval worldwide for a class of drugs called Factor XIa inhibitors, which aim to slow down the activity of a protein that regulates how the body forms clots without increasing the risk of bleeding.